References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality

2024 · External reference

Cancer incidence and mortality worldwide: global burden of disease analysis

2020 · External reference

Unresolved reference

2023 · External reference

The first population-level description of women diagnosed with invasive breast cancer in Costa Rica from 2008 to 2012: a cross-sectional study

10.1177/10732748231193550 · 2023 · External reference

Global cancer statistics 2023: GLOBOCAN estimates of incidence and mortality

2023 · External reference

Unresolved reference

2023 · External reference

Late-stage cancer costs in Latin America: a comparative analysis

2022 · External reference

International evaluation of an AI system for breast cancer screening

10.1038/s41586-019-1799-6 · 2020 · External reference

AI diagnostic accuracy for breast tumor classification in controlled trials

2024 · External reference

Artificial intelligence in global health: opportunities and challenges for low-resource settings

2023 · External reference

AI for equitable cancer care: addressing disparities in low-resource settings

2023 · External reference

Cost-effectiveness of breast cancer screening in India

2024 · External reference

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 statement

10.1016/j.jval.2021.11.1351 · 2022 · External reference

AI-driven breast cancer detection and volumetric density prediction in high-resource settings

2023 · External reference

Improving AI performance in LMICs through local validation

2021 · External reference

Unresolved reference

External reference

Tarifario de honorarios profesionales. San José, Costa Rica; 2024. and medicine

2016 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

2024 · External reference

Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography

2014 · External reference

Increased healthcare costs by later stage cancer diagnosis

10.1186/s12913-022-08457-6 · 2022 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

2023 · External reference

An overview of prognostic factors for long-term survivors of breast cancer

10.1007/s10549-007-9556-1 · 2008 · External reference

Unresolved reference

2023 · External reference

Health utility values of breast cancer treatments and the impact of varying quality-of-life assumptions on cost-effectiveness

10.1002/ijc.34899 · 2024 · External reference

Cancer statistics, 2021

2021 · External reference

Health utility estimates in advanced lung cancer patients: a systematic review

2020 · External reference

Unresolved reference

2021 · External reference

Global cancer surgery: delivering safe, affordable, and timely cancer surgery

2022 · External reference

Volumetric breast density and AI malignancy scores in cancer risk prediction

2023 · External reference

Breast cancer care disparities in Central America

2021 · External reference

A contemporary review of breast cancer risk factors and the role of artificial intelligence

10.3389/fonc.2024.1356014 · 2024 · External reference

Analysis of delayed surgical treatment and oncologic outcomes in clinical Stage I non-small cell lung cancer

2021 · External reference

Diagnostic delay and its impact on survival of patients with lung cancer: a meta-analysis

10.1158/1538-7445.am2017-679 · 2017 · External reference

Economic evaluation of lung cancer screening: a systematic review

2020 · External reference

Low-cost AI tools for breast cancer screening in underserved regions

2021 · External reference

Cost-effectiveness of breast cancer screening and prevention: a systematic review

2021 · External reference

Impact of diagnostic delays on survival in lung cancer: a systematic review

2018 · External reference

Timeliness of lung cancer diagnosis and treatment in LMICs: a systematic review

2022 · External reference

Country-level cost-effectiveness thresholds: initial estimates and the need for further research

10.1016/j.jval.2016.02.017 · 2016 · External reference

What next after GDP-based cost-effectiveness thresholds?

10.12688/gatesopenres.13201.1 · 2020 · External reference

Cost-effectiveness of artificial intelligence–assisted low-dose CT screening for lung cancer in Vietnam: a model-based economic evaluation

2022 · External reference

End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography

10.1038/s41591-019-0447-x · 2019 · External reference

Breast cancer disparities among women in low- and middle-income countries: a global challenge and an opportunity for change

2020 · External reference

Cancer control in Latin America: current challenges and perspectives for universal access

2023 · External reference

Detection of breast cancer with mammography: effect of an artificial intelligence support system

10.1148/radiol.2018181371 · 2019 · External reference

Ensuring fairness in machine learning for health care

2022 · External reference

Cost-effectiveness of CT screening in the National Lung Screening Trial

2014 · External reference

Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross-country data

2018 · External reference

Beyond GDP: context-specific cost-effectiveness thresholds in global health decision-making

2023 · External reference

Cost of diagnostic errors in LMICs: a systematic review

2022 · External reference

Status of breast cancer in Latin America: results of the Breast Cancer Revealed Initiative

10.1016/j.critrevonc.2022.103890 · 2023 · External reference

Economic analysis of population-wide LDCT screening for lung cancer in Australia

2023 · External reference

Screening in scarcity: rethinking cost-effectiveness thresholds for LMICs

2021 · External reference

Unresolved reference

2022 · External reference